Syn2bio S.A. is a biotechnology company based in Warsaw, Poland, that focuses on developing and commercializing innovative radiopharmaceuticals aimed at diagnosing heart diseases. Their primary product, the SYN2 cardiotracer, is designed to assess myocardial perfusion and diagnose coronary artery disease, facilitating the detection of myocardial perfusion disorders and the evaluation of post-heart attack conditions. Founded on August 7, 2025, as a result of a demerger from Synektik S.A., Syn2bio went public on the Warsaw Stock Exchange on April 15, 2026. As of August 25, 2026, the company's stock was priced at 63.60 PLN, with a market capitalization of approximately 549.94 million PLN and 8,729,129 shares outstanding, each with a nominal value of 0.50 PLN. In its first half-year report for the period from October 1, 2025, to March 31, 2026, the company reported total assets of 26.2 million PLN and revenue of 44,000 PLN, with a net loss of 23.7 million PLN. The financial report indicated that Syn2bio had enough funding to support the SYN2 cardiotracer project for about 12–14 months. The company's registered office is located at ul. Józefa Piusa Dziekońskiego 3, 00-728 Warsaw, Poland.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
SYN2BIO SPÓŁKA AKCYJNA's offering is currently approved on OTHER. SYN2BIO SPÓŁKA AKCYJNA is headquartered in Poland. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with SYN2BIO SPÓŁKA AKCYJNA.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/syn2bio-spolka-akcyjna" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="SYN2BIO SPÓŁKA AKCYJNA — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/syn2bio-spolka-akcyjna?theme=light as the src instead.
https://www.discoveripo.com/ipo/syn2bio-spolka-akcyjna/opengraph-image
SYN2BIO SPÓŁKA AKCYJNA IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/syn2bio-spolka-akcyjna?utm_source=embed&utm_medium=text&utm_campaign=syn2bio-spolka-akcyjna
Get emailed when SYN2BIO SPÓŁKA AKCYJNA's terms, price, or expected date change — no weekly noise, just this company.
SYN2BIO SPÓŁKA AKCYJNA is listing on OTHER.
Syn2bio S.A. is a biotechnology company based in Warsaw, Poland, that focuses on developing and commercializing innovative radiopharmaceuticals aimed at diagnosing heart diseases. Their primary product, the SYN2 cardiotracer, is designed to assess myocardial perfusion and diagnose coronary artery disease, facilitating the detection of myocardial perfusion disorders and the evaluation of post-heart attack conditions. Founded on August 7, 2025, as a result of a demerger from Synektik S.A., Syn2bio went public on the Warsaw Stock Exchange on April 15, 2026. As of August 25, 2026, the company's stock was priced at 63.60 PLN, with a market capitalization of approximately 549.94 million PLN and 8,729,129 shares outstanding, each with a nominal value of 0.50 PLN. In its first half-year report for the period from October 1, 2025, to March 31, 2026, the company reported total assets of 26.2 million PLN and revenue of 44,000 PLN, with a net loss of 23.7 million PLN. The financial report indicated that Syn2bio had enough funding to support the SYN2 cardiotracer project for about 12–14 months. The company's registered office is located at ul. Józefa Piusa Dziekońskiego 3, 00-728 Warsaw, Poland.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy